Financing the oligarchs

Hedge funds are snapping up synthetic exposure to illiquid, emerging market companies. Brokered by investment banks keen to provide emerging market investors with financing solutions, the returns can be great, but so too are the risks. By John Ferry

pg55-sremerginmrkt-gif

Russia is the place to make money at the moment. Credit spreads on Russian corporate debt significantly tightened last year, while the country's stock market boomed on the back of rising commodity prices. It's left a small number of wealthy Russian investors with significant and often illiquid equity stakes in companies, looking to raise money against those holdings without actually losing control of them. The solution, arranged by a small number of investment banks, is to provide financing to

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here